AGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AGENUS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.18+0.14 (+2.32%)
Close on Oct 19, 2026
- Market cap
- $255.47M
- P/E (TTM)
- –
- Dividend yield
- –
AGENUS INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-cash royalties [Member] | $117.49M | $114.18M | $108.59M | $103.51M | $99.02M | $96.77M | $100.98M | $128.05M | $123.75M | $123.23M | $114.57M | $79.82M | 88.5% | +18.7% |
| Service Revenue [Member] | $0 | $526.00K | $1.04M | $1.69M | $2.14M | $2.27M | $2.00M | $1.87M | $1.95M | $2.03M | $2.98M | $8.81M | 0.0% | -100.0% |
| Research and Development Revenue [Member] | – | – | – | – | – | – | $482.00K | $30.52M | $33.93M | $36.15M | $38.76M | $12.27M | – | – |
| Research and development services [Member] | – | – | – | – | – | – | – | – | – | – | $1.44M | $1.68M | – | – |
| Other [Member] | – | – | $1.04M | $1.69M | $2.14M | $2.27M | $2.00M | $1.87M | $1.95M | $2.03M | $2.98M | $8.81M | – | – |
| Non-Cash Royalty Revenue Related to the Sale of Future Royalties [Member] | – | – | – | $103.51M | $99.02M | $96.77M | $100.98M | $128.05M | $123.75M | $123.23M | $114.57M | $79.82M | – | – |
| Clinical product revenue [Member] | – | – | – | – | – | – | $482.00K | – | – | – | $116.00K | – | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $132.69M | $123.34M | $113.16M | $105.14M | $99.57M | $97.25M | $101.46M | $158.56M | $157.68M | $159.39M | $153.34M | $92.09M | 100.0% | +33.3% |
| Rest of World [Member] | – | – | $1.04M | $1.69M | $2.14M | $2.27M | $2.00M | $1.87M | $1.95M | $2.03M | $2.98M | $8.81M | – | – |
From the segment and revenue-disaggregation notes of Agenus's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.